A Rundown of Ongoing Psychedelics Clinical Studies

October 29, 2021 10:35:42

The psychedelics space has grown significantly in the last few years, becoming a full-fledged industry with many verticals that range from specialized healthcare services to digital therapeutics and supply chain solutions. Drug discovery and development is arguably the sector’s most observed vertical given that the approval of psychedelic drugs through the clinical trial pipeline is a one-way ticket to revenue for any companies in this space.

Below is a list of some of the clinical trials being conducted in the psychedelics space.

Ongoing phase 1 clinical trials

  • Ceruvia Lifesciences

The company is currently conducting clinical trials for its synthetic psilocybin compound dubbed SYNP-101 and its LSD non-hallucinogenic analog known as NYPRG-101. SYNP-101 is being studied for its use in treating obsessive-compulsive disorder as well as cluster and migraine headaches.

  • Beckley Psytech

This arm of the Beckley Foundation is recruiting for its phase 1 trial, which will evaluate the use of psilocybin in treating chronic short-lasting unilateral neuralgiform headaches.

Phase 1/2 trials

  • DemeRx

The company announced earlier this year that it had received approval to begin recruiting for its phase 1/2a ibogaine clinical trial in treating opioid use disorder.

  • Small Pharma

Small Pharma has partnered with Imperial College London’s Centre for Psychedelic Research for a phase 1/2a trial of DMT in treating depression.

Announced phase 2 trials

  • Eleusis

This company may soon commence phase 2 trials for its two psychedelic infusion therapies for the treatment of major depressive disorder.

  • MindMed

The company recently announced its plans for phase 2 trials in the use of LSD microdosing in managing pain and ADHD.

  • MAPS

Multidisciplinary Association for Psychedelic Studies (“MAPS”) is set to begin a phase 2 trial examining MDMA-assisted cognitive behavioral conjoint therapy in the treatment of post-traumatic stress disorder.

  • Cybin Inc.

Earlier this year, Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) revealed that it had secured approval to begin a phase 2 clinical study evaluating its formulation dubbed CYB001 indicated for the treatment of major depressive disorder.

Ongoing phase 2 trials


The association is also exploring the use of MDMA in treating social anxiety in autistic individuals, anxiety linked to a life-threatening ailment, and eating disorders such as binge eating and anorexia nervosa.

  • Awakn Life Sciences

The company is undertaking a phase 2a/2b trial investigating the use of ketamine in the reduction of alcoholic relapse.

  • Usona Institute

This not-for-profit organization based in Wisconsin is conducting a phase 2 trial investigating psilocybin use in patients with major depressive disorder.

  • Compass Pathways

Compass is conducting a phase 2 trial on its COMP360 psilocybin formulation, which has been developed to manage treatment-resistant depression.

To follow these and other ongoing/planned studies, use this interactive tracker to get the latest on any study you may have an interest in.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.